Stocks Health care NXTC
NASDAQ · Health careNextCure, Inc. (NXTC)
It posted a net loss of $42.7M. At June 30, 2026 it held $15.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about NextCure, Inc.
- Net worth
- NextCure, Inc. has a market value (market cap) of $27.4M at the latest share price, and shareholders' equity of $12.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2020 revenue was $22.4M (+252.6% year on year), with a net loss of $36.6M.
- Cash flow
- In fiscal 2025 operations used $49.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- NextCure, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What NextCure, Inc. does
NextCure, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker NXTC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$55.8M | -$19.65 | n/a |
| 2024 | n/a | -$55.7M | -$23.88 | -$41.3M |
| 2023 | n/a | -$62.7M | -$27.00 | -$53.8M |
| 2022 | n/a | -$74.7M | -$32.28 | -$56M |
| 2021 | n/a | -$69.4M | -$30.12 | -$59.6M |
| 2020 | $22.4M | -$36.6M | -$15.96 | -$52.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What NextCure, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 1, 2026
- September 25, 2026Form 425 filing 425
- September 25, 2026Other event 8-K
- September 3, 2026
- August 18, 2026
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running NextCure, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| August 10, 2026 | Simcere Zaiming, Inc.Former 10% Owner | Soldindirect | 30,000 | $184.8K |
| July 31, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 3,300 | $16.4K |
| July 31, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 25,000 | $124.5K |
| July 31, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 8,003 | $38.4K |
| July 30, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 50,000 | $248.6K |
| July 30, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 20,000 | $100K |
| July 30, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 20,000 | $100K |
| July 30, 2026 | ADAR1 Capital Management, LLC10% owner | Boughtindirect | 25,000 | $120.3K |
Who owns NXTC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| ADAR1 Capital Management, LLC13G, passive with 1 related filers | 15.8% | August 14, 2026 |
| Ikarian Capital, LLC13G, passive with 1 related filers | 9.99% | August 14, 2026 |
| Simcere Zaiming, Inc.13G, passive with 5 related filers | 9.4% | May 6, 2026 |
| Affinity Healthcare Fund, LP (EIN 82-1629802)13G, passive with 1 related filers | 8.22% | November 13, 2024 |
| Adage Capital Management, L.P.13G, passive with 2 related filers | 7.67% | August 12, 2026 |
| Sofinnova Venture Partners IX, L.P. ("SVP IX")13D, may seek influence with 2 related filers | 7.1% | March 5, 2026 |
| Affinity Asset Advisors, LLC13G, passive with 1 related filers | 6.4% | August 13, 2026 |
Largest institutional holders
Insiders
2 insiders reported holding 1,031,055 shares in total, about $6.2M at the last price.
| Holder | Shares |
|---|---|
| ADAR1 Capital Management, LLC10% owner | 722,419722,419 held indirectly |
| Simcere Zaiming, Inc.Former 10% Owner | 308,636308,636 held indirectly |
Questions about NXTC
What does NextCure, Inc. do?
NextCure, Inc. is a company in the Health care sector, listed on NASDAQ as NXTC. Its shares trade on NASDAQ under the ticker NXTC.
What is NextCure, Inc.'s net worth?
NextCure, Inc. has a market value (market cap) of $27.4M at the latest share price, and shareholders' equity of $12.1M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is NextCure, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $42.7M.
When did NextCure, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration (amended) from October 1, 2026.
When is NextCure, Inc.'s next earnings report?
NextCure, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare NXTC with
Follow NXTC
Get an email when NextCure, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values NextCure, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.